インサイダー取引

EDGAR

XOMA Corp

取締役、役員、10%超の株主がSECのForm 3、4、5で報告した取引を、各提出書類のXMLから読み取っています。コードとその文言はSEC自身のものです。

Form 4は取引から2営業日以内に提出する必要があるため、直近の取引はまだ提出されていない場合があります。

期間:2025年11月16日以降の日付の取引。

市場での購入(コードP)
1件の取引、100,000株
株数 × 1株あたり価格の合計:2,505,000
市場での売却(コードS)
0件の取引、—株

合計は掲載した提出済み取引を足したもので、報告された内容の集計であり、方向性を示すものではありません。

121件中1–50件を表示

SECのForm 3、4、5で提出されたインサイダー取引(新しい順)
日付報告者コード取得または処分株数1株あたり価格(提出どおり)価値(算出)取引後の保有株数直接または間接ルール10b5-1のチェック欄注記出典
2026年7月14日 2026年7月16日に提出BVF PARTNERS L P/IL 10% ownerBIOTECHNOLOGY VALUE FUND L P 10% ownerBVF I GP LLC 10% ownerBIOTECHNOLOGY VALUE FUND II LP 10% ownerBVF II GP LLC 10% ownerBiotechnology Value Trading Fund OS LP Other: See Explanation of ResponsesBVF Partners OS Ltd. Other: See Explanation of ResponsesBVF GP HOLDINGS LLC 10% ownerBVF INC/IL 10% ownerLAMPERT MARK N 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock, $0.0075 par value per share
処分(D)3,635,758——0直接(D) いいえ
F1, F2, F7, F3
  • F1 This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP (Trading Fund OS), BVF Partners OS Ltd. (Partners OS), BVF I GP LLC (BVF GP), BVF II GP LLC (BVF2 GP), BVF GP Holdings LLC (BVF GPH), BVF Partners L.P. (Partners), BVF Inc. and Mark N. Lampert (collectively, the Reporting Persons). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  • F2 This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among the Issuer, Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the Merger).
  • F7 The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments.
  • F3 Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
提出書類を開く 0000921895-26-001823 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月16日に提出BVF PARTNERS L P/IL 10% ownerBIOTECHNOLOGY VALUE FUND L P 10% ownerBVF I GP LLC 10% ownerBIOTECHNOLOGY VALUE FUND II LP 10% ownerBVF II GP LLC 10% ownerBiotechnology Value Trading Fund OS LP Other: See Explanation of ResponsesBVF Partners OS Ltd. Other: See Explanation of ResponsesBVF GP HOLDINGS LLC 10% ownerBVF INC/IL 10% ownerLAMPERT MARK N 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock, $0.0075 par value per share
処分(D)2,773,545——0直接(D) いいえ
F1, F2, F7, F4
  • F1 This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP (Trading Fund OS), BVF Partners OS Ltd. (Partners OS), BVF I GP LLC (BVF GP), BVF II GP LLC (BVF2 GP), BVF GP Holdings LLC (BVF GPH), BVF Partners L.P. (Partners), BVF Inc. and Mark N. Lampert (collectively, the Reporting Persons). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  • F2 This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among the Issuer, Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the Merger).
  • F7 The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments.
  • F4 Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
提出書類を開く 0000921895-26-001823 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月16日に提出BVF PARTNERS L P/IL 10% ownerBIOTECHNOLOGY VALUE FUND L P 10% ownerBVF I GP LLC 10% ownerBIOTECHNOLOGY VALUE FUND II LP 10% ownerBVF II GP LLC 10% ownerBiotechnology Value Trading Fund OS LP Other: See Explanation of ResponsesBVF Partners OS Ltd. Other: See Explanation of ResponsesBVF GP HOLDINGS LLC 10% ownerBVF INC/IL 10% ownerLAMPERT MARK N 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock, $0.0075 par value per share
処分(D)412,000——0直接(D) いいえ
F1, F2, F7, F5
  • F1 This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP (Trading Fund OS), BVF Partners OS Ltd. (Partners OS), BVF I GP LLC (BVF GP), BVF II GP LLC (BVF2 GP), BVF GP Holdings LLC (BVF GPH), BVF Partners L.P. (Partners), BVF Inc. and Mark N. Lampert (collectively, the Reporting Persons). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  • F2 This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among the Issuer, Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the Merger).
  • F7 The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments.
  • F5 Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
提出書類を開く 0000921895-26-001823 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月16日に提出BVF PARTNERS L P/IL 10% ownerBIOTECHNOLOGY VALUE FUND L P 10% ownerBVF I GP LLC 10% ownerBIOTECHNOLOGY VALUE FUND II LP 10% ownerBVF II GP LLC 10% ownerBiotechnology Value Trading Fund OS LP Other: See Explanation of ResponsesBVF Partners OS Ltd. Other: See Explanation of ResponsesBVF GP HOLDINGS LLC 10% ownerBVF INC/IL 10% ownerLAMPERT MARK N 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock, $0.0075 par value per share
処分(D)772,000——0間接(I) See footnoteいいえ
F1, F2, F7, F6
  • F1 This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP (Trading Fund OS), BVF Partners OS Ltd. (Partners OS), BVF I GP LLC (BVF GP), BVF II GP LLC (BVF2 GP), BVF GP Holdings LLC (BVF GPH), BVF Partners L.P. (Partners), BVF Inc. and Mark N. Lampert (collectively, the Reporting Persons). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  • F2 This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among the Issuer, Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the Merger).
  • F7 The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments.
  • F6 Securities held in certain Partners managed accounts (the Partners Managed Accounts). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts.
提出書類を開く 0000921895-26-001823 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hughes Owen Director · Officer: Chief Executive Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)191,264——0直接(D) いいえ
F1, F2, F3
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F3 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
提出書類を開く 0001193125-26-303725 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hughes Owen Director · Officer: Chief Executive Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)752——0間接(I) By 401(k) Planいいえ
F1, F2
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
提出書類を開く 0001193125-26-303725 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hughes Owen Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Depositary Shares - 8.375% Series B Cumulative Stock
処分(D)102,000——0直接(D) いいえ
F1, F4
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer (including the Depositary Shares) was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
提出書類を開く 0001193125-26-303725 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hughes Owen Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (100,000) — 行使価格 18.66
処分(D)100,0000—0直接(D) いいえ
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303725 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hughes Owen Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (75,000) — 行使価格 30
処分(D)75,0000—0直接(D) いいえ
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303725 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hughes Owen Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Performance Stock Units — 原資産 Common Stock (116,245)
処分(D)116,2450—0直接(D) いいえ
F1, F7, F8
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F7 Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award (PSU) automatically converted into and was substituted with a restricted stock unit award (each, a Converted PSU) with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the Target Shares (as the term Target Shares is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of Target Shares as to which, as of immediately prior to the Effective Time, the Performance-Requirement has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the Target Shares underlying such PSU as to which the Performance-Requirement would be satisfied if the Closing Price (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over
  • F8 (Continued from footnote 7) (B) the number of Target Shares as to which, as of immediately prior to the Effective Time, the Performance-Requirement has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU.
提出書類を開く 0001193125-26-303725 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hughes Owen Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Performance Stock Units — 原資産 Common Stock (132,714)
処分(D)132,7140—0直接(D) いいえ
F1, F7, F8
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F7 Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award (PSU) automatically converted into and was substituted with a restricted stock unit award (each, a Converted PSU) with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the Target Shares (as the term Target Shares is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of Target Shares as to which, as of immediately prior to the Effective Time, the Performance-Requirement has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the Target Shares underlying such PSU as to which the Performance-Requirement would be satisfied if the Closing Price (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over
  • F8 (Continued from footnote 7) (B) the number of Target Shares as to which, as of immediately prior to the Effective Time, the Performance-Requirement has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU.
提出書類を開く 0001193125-26-303725 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Franklin Heather L Director
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)6,269——0直接(D) いいえ
F1, F2, F3
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F3 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
提出書類を開く 0001193125-26-303719 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Franklin Heather L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (17,282) — 行使価格 31.39
処分(D)17,2820—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303719 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Franklin Heather L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (8,996) — 行使価格 17.86
処分(D)8,9960—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303719 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Franklin Heather L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (10,967) — 行使価格 21.39
処分(D)10,9670—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303719 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Franklin Heather L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (9,763) — 行使価格 24.71
処分(D)9,7630—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303719 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Kosacz Barbara Director
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)6,269——0直接(D) いいえ
F1, F2, F3
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F3 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
提出書類を開く 0001193125-26-303726 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (19,979) — 行使価格 12.65
処分(D)19,9790—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303726 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (8,167) — 行使価格 15.59
処分(D)8,1670—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303726 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (6,152) — 行使価格 21.27
処分(D)6,1520—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303726 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,101) — 行使価格 31.04
処分(D)5,1010—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303726 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (8,996) — 行使価格 17.86
処分(D)8,9960—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303726 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (10,967) — 行使価格 21.39
処分(D)10,9670—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303726 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (9,763) — 行使価格 24.71
処分(D)9,7630—0直接(D) いいえ
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303726 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)9,532——0直接(D) いいえ
F1, F2, F3
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F3 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

8.625% Series A Cumulative Perpetual Preferred Stock
処分(D)10,000——0直接(D) いいえ
F1, F4
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Depositary Shares - 8.375% Series B Cumulative Stock
処分(D)20,000——0直接(D) いいえ
F1, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer (including the Depositary Shares) was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (8,000) — 行使価格 4.03
処分(D)8,0000—0直接(D) いいえ
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (2,366) — 行使価格 19.4
処分(D)2,3660—0直接(D) いいえ
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,052) — 行使価格 25.16
処分(D)5,0520—0直接(D) いいえ
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (8,167) — 行使価格 15.59
処分(D)8,1670—0直接(D) いいえ
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (6,152) — 行使価格 21.27
処分(D)6,1520—0直接(D) いいえ
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,101) — 行使価格 31.04
処分(D)5,1010—0直接(D) いいえ
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (8,996) — 行使価格 17.86
処分(D)8,9960—0直接(D) いいえ
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (10,967) — 行使価格 21.39
処分(D)10,9670—0直接(D) いいえ
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (9,763) — 行使価格 24.71
処分(D)9,7630—0直接(D) いいえ
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (9,936) — 行使価格 25.12
処分(D)9,9360—0直接(D) いいえ
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303727 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hernday Natasha Director
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)9,304——0直接(D) いいえ
F1, F2, F3
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F3 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
提出書類を開く 0001193125-26-303723 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

8.625% Series A Cumulative Perpetual Preferred Stock
処分(D)4,000——0直接(D) いいえ
F1, F4
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
提出書類を開く 0001193125-26-303723 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (13,251) — 行使価格 19.76
処分(D)13,2510—0直接(D) いいえ
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303723 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,101) — 行使価格 31.04
処分(D)5,1010—0直接(D) いいえ
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303723 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (8,996) — 行使価格 17.86
処分(D)8,9960—0直接(D) いいえ
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303723 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (10,967) — 行使価格 21.39
処分(D)10,9670—0直接(D) いいえ
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303723 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (4,881) — 行使価格 24.71
処分(D)4,8810—0直接(D) いいえ
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
提出書類を開く 0001193125-26-303723 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Sitko Bradley Officer: Chief Investment Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)83,765——0直接(D) いいえ
F1, F2, F3, F4
  • F1 Includes 804 shares acquired under the ESPP Plan on May 31, 2026.
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F3 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
提出書類を開く 0001193125-26-303722 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Sitko Bradley Officer: Chief Investment Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

8.625% Series A Cumulative Perpetual Preferred Stock
処分(D)313——0直接(D) いいえ
F2, F5
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
提出書類を開く 0001193125-26-303722 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Sitko Bradley Officer: Chief Investment Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Depositary Shares - 8.375% Series B Cumulative Stock
処分(D)7,045——0直接(D) いいえ
F2, F6
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer (including the Depositary Shares) was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
提出書類を開く 0001193125-26-303722 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Sitko Bradley Officer: Chief Investment Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)1,287——0間接(I) By 401(k)いいえ
F2, F3
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F3 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
提出書類を開く 0001193125-26-303722 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Sitko Bradley Officer: Chief Investment Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)75——0間接(I) By childいいえ
F2, F3
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F3 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
提出書類を開く 0001193125-26-303722 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月14日 2026年7月14日に提出Sitko Bradley Officer: Chief Investment Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)75——0間接(I) By childいいえ
F2, F3
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F3 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
提出書類を開く 0001193125-26-303722 提出書類のXMLから読み取り この行に異議を申し立てる

機関投資家の保有(Form 13F)

2026-09-30終了の四半期:提出書類7,211件を読み込み、最新の提出日は2026年11月13日です。 2026-06-30終了の前四半期:提出書類9,150件を読み込みました。

1件中1–1件を表示

機関投資家の保有(大きい順、提出どおり)
運用者株数または元本提出どおりの価値前四半期との差出典
Allworth Financial LP 21 SH893 ドル変化なし 前四半期:21提出書類を開く 0001140361-26-042358 2026年11月6日に提出 この行に異議を申し立てる
前四半期にあり、最新四半期の提出書類を読み込んでいない運用者

単にまだ提出していない可能性があります。最新四半期の読み込み済み提出書類にないことは、売却を意味しません。

  • BVF INC/IL 7,593,303 SH
  • MORGAN STANLEY 1,697,167 SH
  • FMR LLC 1,605,532 SH
  • Woodline Partners LP 1,114,363 SH
  • Newtyn Management, LLC 709,247 SH
  • BlackRock, Inc. 691,971 SH
  • VANGUARD CAPITAL MANAGEMENT LLC 505,165 SH
  • Opaleye Management Inc. 338,374 SH
  • GEODE CAPITAL MANAGEMENT, LLC 245,321 SH
  • WATER ISLAND CAPITAL LLC 242,000 SH
  • ALPINE ASSOCIATES MANAGEMENT INC. 239,318 SH
  • STATE STREET CORP 197,764 SH
  • MILLENNIUM MANAGEMENT LLC 196,307 SH
  • DIMENSIONAL FUND ADVISORS LP 177,106 SH
  • HSBC HOLDINGS PLC 149,523 SH
  • NORTHERN TRUST CORP 96,179 SH
  • VANGUARD PORTFOLIO MANAGEMENT LLC 90,348 SH
  • TUDOR INVESTMENT CORP ET AL 84,391 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 83,623 SH
  • TORNO CAPITAL, LLC 80,000 SH
  • Bank of New York Mellon Corp 75,348 SH
  • Verition Fund Management LLC 70,601 SH
  • VANGUARD FIDUCIARY TRUST CO 70,189 SH
  • Simcoe Capital LLC 68,053 SH
  • Groupe la Francaise 52,276 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 50,400 SH
  • TLS Advisors LLC 42,165 SH
  • TORNO CAPITAL, LLC 41,000 SH
  • TWO SIGMA INVESTMENTS, LP 36,744 SH
  • XTX Topco Ltd 35,046 SH
  • CREDIT INDUSTRIEL ET COMMERCIAL 34,853 SH
  • Balyasny Asset Management L.P. 34,621 SH
  • JANE STREET GROUP, LLC 32,100 SH
  • MILLENNIUM MANAGEMENT LLC 30,200 SH
  • JPMORGAN CHASE CO 30,018 SH
  • RBF Capital, LLC 30,000 SH
  • CITADEL ADVISORS LLC 28,460 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 28,078 SH
  • Sixth Street Partners Management Company, L.P. 28,078 SH
  • EQUITEC PROPRIETARY MARKETS, LLC 28,000 SH
  • GROUP ONE TRADING LLC 27,200 SH
  • SIERRA SUMMIT ADVISORS LLC 25,740 SH
  • UBS Group AG 23,843 SH
  • GOLDMAN SACHS GROUP INC 20,122 SH
  • CSS LLC/IL 19,561 SH
  • TORNO CAPITAL, LLC 18,700 SH
  • Nuveen, LLC 18,388 SH
  • JANE STREET GROUP, LLC 18,192 SH
  • MARTINGALE ASSET MANAGEMENT L P 12,200 SH
  • RHUMBLINE ADVISERS 11,451 SH
  • Form 13Fは第13(f)条対象証券のロング・ポジションのみを対象とし、ショートや同リスト外の証券は含みません。
  • 最新四半期をまだ提出していない運用者はゼロではなく不在です。提出期限は四半期末から最長45日です。
  • 差は2つの四半期末時点の差であり、取引ではありません。
  • 別の運用者の名義で報告された保有は、その運用者の提出書類にも現れることがあるため、行を合算しないでください。
  • 証券リストがこの会社に結び付けられない、または曖昧にしか結び付けられない保有は表示しません。

5%保有者(Schedule 13D・13G)

SECの構造化形式(2024年末以降)で提出されたスケジュールをここで読み取ります。それ以前のものは自由形式のテキストで、読み取っていません。

5%保有者(新しい事由順、提出どおり)
保有者クラスに占める割合保有株数事由日書式出典
Morgan Stanley Common Stock0.0007/31/2026 2026年8月7日に提出SCHEDULE 13G/A訂正 4提出書類を開く 0000895421-26-000217 この行に異議を申し立てる
Morgan Stanley Investment Management Inc. Common Stock0007/31/2026 2026年8月7日に提出SCHEDULE 13G/A訂正 4提出書類を開く 0000895421-26-000217 この行に異議を申し立てる
FMR LLC COMMON STOCK0.00.0007/31/2026 2026年8月7日に提出SCHEDULE 13G/A訂正 7提出書類を開く 0000315066-26-002250 この行に異議を申し立てる
Abigail P. Johnson COMMON STOCK0.00.0007/31/2026 2026年8月7日に提出SCHEDULE 13G/A訂正 7提出書類を開く 0000315066-26-002250 この行に異議を申し立てる
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0075 par value00.0007/14/2026 2026年7月16日に提出SCHEDULE 13D/A訂正 15提出書類を開く 0000921895-26-001822 この行に異議を申し立てる
BVF I GP LLC Common Stock, $0.0075 par value00.0007/14/2026 2026年7月16日に提出SCHEDULE 13D/A訂正 15提出書類を開く 0000921895-26-001822 この行に異議を申し立てる
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0075 par value00.0007/14/2026 2026年7月16日に提出SCHEDULE 13D/A訂正 15提出書類を開く 0000921895-26-001822 この行に異議を申し立てる
BVF II GP LLC Common Stock, $0.0075 par value00.0007/14/2026 2026年7月16日に提出SCHEDULE 13D/A訂正 15提出書類を開く 0000921895-26-001822 この行に異議を申し立てる
Biotechnology Value Trading Fund OS LP Common Stock, $0.0075 par value00.0007/14/2026 2026年7月16日に提出SCHEDULE 13D/A訂正 15提出書類を開く 0000921895-26-001822 この行に異議を申し立てる
BVF Partners OS Ltd. Common Stock, $0.0075 par value00.0007/14/2026 2026年7月16日に提出SCHEDULE 13D/A訂正 15提出書類を開く 0000921895-26-001822 この行に異議を申し立てる
BVF GP HOLDINGS LLC Common Stock, $0.0075 par value00.0007/14/2026 2026年7月16日に提出SCHEDULE 13D/A訂正 15提出書類を開く 0000921895-26-001822 この行に異議を申し立てる
BVF PARTNERS L P/IL Common Stock, $0.0075 par value00.0007/14/2026 2026年7月16日に提出SCHEDULE 13D/A訂正 15提出書類を開く 0000921895-26-001822 この行に異議を申し立てる
BVF INC/IL Common Stock, $0.0075 par value00.0007/14/2026 2026年7月16日に提出SCHEDULE 13D/A訂正 15提出書類を開く 0000921895-26-001822 この行に異議を申し立てる
LAMPERT MARK N Common Stock, $0.0075 par value00.0007/14/2026 2026年7月16日に提出SCHEDULE 13D/A訂正 15提出書類を開く 0000921895-26-001822 この行に異議を申し立てる
Morgan Stanley Common Stock9.51,686,49506/30/2026 2026年8月7日に提出SCHEDULE 13G/A訂正 3提出書類を開く 0000895421-26-000216 この行に異議を申し立てる
Morgan Stanley Investment Management Inc. Common Stock9.51,685,49306/30/2026 2026年8月7日に提出SCHEDULE 13G/A訂正 3提出書類を開く 0000895421-26-000216 この行に異議を申し立てる
FMR LLC COMMON STOCK9.11,605,532.1406/30/2026 2026年8月6日に提出SCHEDULE 13G/A訂正 6提出書類を開く 0000315066-26-002202 この行に異議を申し立てる
Abigail P. Johnson COMMON STOCK9.11,605,532.1406/30/2026 2026年8月6日に提出SCHEDULE 13G/A訂正 6提出書類を開く 0000315066-26-002202 この行に異議を申し立てる
Vanguard Capital Management Common Stock3.23571,82306/30/2026 2026年7月31日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0002100119-26-001505 この行に異議を申し立てる
BlackRock, Inc. Common Stock3.9685,77206/30/2026 2026年7月30日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0002012383-26-003132 この行に異議を申し立てる
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0075 par value20.73,635,758.0005/14/2026 2026年5月18日に提出SCHEDULE 13D/A訂正 14提出書類を開く 0000921895-26-001434 この行に異議を申し立てる
BVF I GP LLC Common Stock, $0.0075 par value20.73,635,758.0005/14/2026 2026年5月18日に提出SCHEDULE 13D/A訂正 14提出書類を開く 0000921895-26-001434 この行に異議を申し立てる
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0075 par value15.82,773,545.0005/14/2026 2026年5月18日に提出SCHEDULE 13D/A訂正 14提出書類を開く 0000921895-26-001434 この行に異議を申し立てる
BVF II GP LLC Common Stock, $0.0075 par value15.82,773,545.0005/14/2026 2026年5月18日に提出SCHEDULE 13D/A訂正 14提出書類を開く 0000921895-26-001434 この行に異議を申し立てる
Biotechnology Value Trading Fund OS LP Common Stock, $0.0075 par value2.3412,000.0005/14/2026 2026年5月18日に提出SCHEDULE 13D/A訂正 14提出書類を開く 0000921895-26-001434 この行に異議を申し立てる
BVF Partners OS Ltd. Common Stock, $0.0075 par value2.3412,000.0005/14/2026 2026年5月18日に提出SCHEDULE 13D/A訂正 14提出書類を開く 0000921895-26-001434 この行に異議を申し立てる
BVF GP HOLDINGS LLC Common Stock, $0.0075 par value36.56,409,303.0005/14/2026 2026年5月18日に提出SCHEDULE 13D/A訂正 14提出書類を開く 0000921895-26-001434 この行に異議を申し立てる
BVF PARTNERS L P/IL Common Stock, $0.0075 par value43.37,593,303.0005/14/2026 2026年5月18日に提出SCHEDULE 13D/A訂正 14提出書類を開く 0000921895-26-001434 この行に異議を申し立てる
BVF INC/IL Common Stock, $0.0075 par value43.37,593,303.0005/14/2026 2026年5月18日に提出SCHEDULE 13D/A訂正 14提出書類を開く 0000921895-26-001434 この行に異議を申し立てる
LAMPERT MARK N Common Stock, $0.0075 par value43.37,593,303.0005/14/2026 2026年5月18日に提出SCHEDULE 13D/A訂正 14提出書類を開く 0000921895-26-001434 この行に異議を申し立てる
Ligand Pharmaceuticals Incorporated Common Stock, par value $0.0075 per share47.08,062,678.0004/27/2026 2026年5月1日に提出SCHEDULE 13D提出書類を開く 0001193125-26-202033 この行に異議を申し立てる
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0075 par value10.91,322,758.0004/27/2026 2026年4月29日に提出SCHEDULE 13D/A訂正 13提出書類を開く 0000921895-26-001116 この行に異議を申し立てる
BVF I GP LLC Common Stock, $0.0075 par value10.91,322,758.0004/27/2026 2026年4月29日に提出SCHEDULE 13D/A訂正 13提出書類を開く 0000921895-26-001116 この行に異議を申し立てる
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0075 par value10.51,267,545.0004/27/2026 2026年4月29日に提出SCHEDULE 13D/A訂正 13提出書類を開く 0000921895-26-001116 この行に異議を申し立てる
BVF II GP LLC Common Stock, $0.0075 par value10.51,267,545.0004/27/2026 2026年4月29日に提出SCHEDULE 13D/A訂正 13提出書類を開く 0000921895-26-001116 この行に異議を申し立てる
Biotechnology Value Trading Fund OS LP Common Stock, $0.0075 par value00.0004/27/2026 2026年4月29日に提出SCHEDULE 13D/A訂正 13提出書類を開く 0000921895-26-001116 この行に異議を申し立てる
BVF Partners OS Ltd. Common Stock, $0.0075 par value00.0004/27/2026 2026年4月29日に提出SCHEDULE 13D/A訂正 13提出書類を開く 0000921895-26-001116 この行に異議を申し立てる
BVF GP HOLDINGS LLC Common Stock, $0.0075 par value21.42,590,303.0004/27/2026 2026年4月29日に提出SCHEDULE 13D/A訂正 13提出書類を開く 0000921895-26-001116 この行に異議を申し立てる
BVF PARTNERS L P/IL Common Stock, $0.0075 par value21.42,590,303.0004/27/2026 2026年4月29日に提出SCHEDULE 13D/A訂正 13提出書類を開く 0000921895-26-001116 この行に異議を申し立てる
BVF INC/IL Common Stock, $0.0075 par value21.42,590,303.0004/27/2026 2026年4月29日に提出SCHEDULE 13D/A訂正 13提出書類を開く 0000921895-26-001116 この行に異議を申し立てる
LAMPERT MARK N Common Stock, $0.0075 par value21.42,590,303.0004/27/2026 2026年4月29日に提出SCHEDULE 13D/A訂正 13提出書類を開く 0000921895-26-001116 この行に異議を申し立てる
Woodline Partners LP Common Stock, par value $0.00755.4640,001.0003/31/2026 2026年5月15日に提出SCHEDULE 13G提出書類を開く 0000919574-26-003229 この行に異議を申し立てる
Vanguard Capital Management Common Stock5.15613,45803/31/2026 2026年4月30日に提出SCHEDULE 13G提出書類を開く 0002100119-26-001264 この行に異議を申し立てる
BlackRock, Inc. Common Stock5.4640,54903/31/2026 2026年4月27日に提出SCHEDULE 13G提出書類を開く 0002012383-26-001729 この行に異議を申し立てる
The Vanguard Group Common Stock0003/13/2026 2026年3月27日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0000102909-26-002623 この行に異議を申し立てる
FMR LLC COMMON STOCK10.21,268,506.1402/27/2026 2026年3月6日に提出SCHEDULE 13G/A訂正 5提出書類を開く 0000315066-26-000644 この行に異議を申し立てる
Abigail P. Johnson COMMON STOCK10.21,268,506.1402/27/2026 2026年3月6日に提出SCHEDULE 13G/A訂正 5提出書類を開く 0000315066-26-000644 この行に異議を申し立てる
Morgan Stanley Common Stock13.71,702,54512/31/2025 2026年2月12日に提出SCHEDULE 13G/A訂正 2提出書類を開く 0000895421-26-000069 この行に異議を申し立てる
Morgan Stanley Investment Management Inc. Common Stock13.71,700,92512/31/2025 2026年2月12日に提出SCHEDULE 13G/A訂正 2提出書類を開く 0000895421-26-000069 この行に異議を申し立てる
FMR LLC COMMON STOCK9.01,079,588.1406/30/2025 2025年8月6日に提出SCHEDULE 13G/A訂正 4提出書類を開く 0000315066-25-002157 この行に異議を申し立てる

割合は提出書類が指定するクラスに対するもので、保有者の申告どおりです。グループの構成員はそれぞれグループの株式を報告するため、行を合算しないでください。

読み込んだ内容

2004年6月14日から2026年11月13日までの提出書類2,102,727件を読み込み:Form 3, 3/A, 4, 4/A, 5, 5/A。

アーカイブの読み込み中は、不完全な年があります。ここで提出数が少ない年が、実際に少なかったという意味ではありません。

提出年別の読み込み件数
提出年読み込み件数
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024195,705
2025235,520
2026254,737

SECがXMLを義務付ける前の提出書類は一覧にあるだけで、内容は抽出していません。

XOMA Corpに戻る